Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A small randomized controlled trial with a statistically significant primary endpoint (p=0.0008) and reported improvements in swallowing, voice, and GRBAS scores, but limited by modest sample size, lack of reported effect sizes, and insufficient detail on methods and follow-up.
This is a narrative review proposing mechanistic pathways and therapeutic approaches for neuropsychiatric comorbidity in systemic sclerosis, without new empirical data or clinical trials to test these hypotheses.